Spravato (Esketamine) for Treatment Resistant DepressionMarch 6, 2019
Spravato is a drug-device combination consisting of esketamine for intranasal administration intended for the treatment of treatment resistant depression. Spravato is the s-enantiomer of ketamine, an FDA-approved general anesthetic agent. Spravato is a more potent anesthetic than ketamine, but has a more rapid metabolism. Spravato has been designated a Schedule III controlled substance, and may be subject to abuse and diversion.
If you have a Hayes login, click here to view the full report on the Knowledge Center.